Harbor BioSciences intends to explore distribution and business partners to participate in and help implement the distribution of CIPI's drug portfolio. Organizations with existing distribution networks or that may have an interest in rapidly establishing efficient and competitive new networks would be ideal candidates for potential partnerships.
and whom do you think will be distributing hrbr's drugs - Apoptone, Triolex, and HE2000 - once (and of course if) they get approved by the SFDA? so any of the counterparties that hrbr may have been wooing but were afraid to commit because the approval path could be long, now have an incentive to hop to. yikes! how can this be seventeen cents offered? some very very nearsighted folks out there.
I am, as always, in awe of the way the market pummels hrbr. but this time, I think, whether the market likes it or not, they've got a ticket to a pretty interesting future. IF they start doing good things just with this CIPI distribution opportunity, they could make some hefty change. so once again we'll wait to see what the next rabbit out of the hat will be: still no proxy filing so something's still in the works (or they're saving money :o)).